A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

Author:

Kirwin ErinORCID,Rafferty Ellen,Harback Kate,Round Jeff,McCabe Christopher

Abstract

AbstractOBJECTIVEWe implement a model-based approach to identify the optimal allocation of a COVID-19 vaccine in the province of Alberta, Canada.METHODSWe develop an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness, and cost of vaccine. The model simulates hypothetical immunization scenarios within a dynamic context, capturing concurrent public health strategies and population behaviour changes.RESULTSIn a scenario with 80% vaccine effectiveness, 40% population coverage, and prioritisation of those over the age of 60 at high-risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs. 292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs. 118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies.CONCLUSIONSOur results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised.

Publisher

Cold Spring Harbor Laboratory

Reference43 articles.

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 2021. https://covid19.who.int/?gclid=Cj0KCQjw3ZX4BRDmARIsAFYh7ZLuu8BFL-gYbXtg5OMm4L_P4oqdQ7gbHn9wgTBVlIIaKzHD0bPfRU0aAhoWEALw_wcB. Accessed 2021-03- 12 2021.

2. World Health Organization. The push for a COVID-19 vaccine. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines?gclid=CjwKCAjwz6_8BRBkEiwA3p02VfNzp6CQFFczxUolOmCLjurVQzu8eglhw54TctCLTwDrLoW1ONAfrRoCQFwQAvD_BwE. Accessed 2021/03/12.

3. Government of Canada. Drug and vaccine authorizations for COVID-19: List of applications received. 2021. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html#wb-auto-4. Accessed 2021/03/12.

4. Hassoun N. How to Distribute a COVID-19 Vaccine Ethically. Scientific American. 2020 2020/9/25.

5. Kupferschmidt K. WHO unveils global plan to fairly distribute COVID-19 vaccine, but challenges await. Science Magazine. 2020 2020/9/21.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3